Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/43088


Wyeth: Performance, Products, Pipeline and Potential


Description: Wyeth is one of the world’s largest research-based pharmaceutical and healthcare products companies and is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, biotechnology products, vaccines, non-prescription medicines and animal health products. Wyeth currently operates in over 145 countries worldwide.

Fiscal 2007 was a strong year for Wyeth, with the company achieving record levels of sales and income. In terms of pharmaceuticals sales, Wyeth maintained its place in the top ten research-based pharmaceutical companies worldwide. This success was based on strong growth of its biotechnology products Enbrel and Prevnar, the launch of Torisel and Lybrel, and the company's continued expansion into China, the Middle East and Latin America. Furthermore, Wyeth reported successful cost-management efforts through the efficient implementation of its ""Project Springboard"" scheme.

Wyeth’s growth is based on a strong foundation of products, which includes Effexor, Protonix, Enbrel, Prevnar, Zosyn, and the Premarin franchise. Productivity, coupled with significant investment in facilities (for example, Wyeth’s US$2 billion biotech manufacturing site in Grange Castle, Ireland) allowed the company to achieve record levels of production for its lead vaccine, Prevnar, and accommodation of the increasing demand for Enbrel, which is fast becoming one of the world’s leading rheumatoid arthritis treatments.

However, sustained growth is threatened by the loss of patent protection for several products including Effexor (Wyeth’s top-seller), Prevnar and Zosyn. Wyeth has assembled a strong pipeline, which may yield compounds to follow in the footsteps of these leading products. Desvenlafaxine and the 13-valent pneumococcal vaccine have the potential to succeed Effexor and Prevnar respectively, whilst the recently-launched Tygacil is anticipated to provide a boost to the Anti-infective therapeutic area, whose sales were set to suffer with the loss of Zosyn’s market protection.


Contents: EXECUTIVE SUMMARY
A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis.

THERAPEUTIC AREA FOCUS
Key product analysis and forecasting

Neuroscience
Effexor (venlafaxine)
Pristiq (desvenlafaxine succinate)

Gastroenterology
Protonix (pantoprazole)
Relistor (methylnaltrexone)

Vaccines
Prevnar/Prevenar (7-valent glycoconjugate)

Musculoskeletal
Enbrel (etanercept)
rhBMP-2/Inductos (dibotermin alpha)

Women's Healthcare/Contraception
Lybrel/Anya (levonorgestral+ethinyloestradiol)
Oral contraceptives
Premarin (conjugated oestrogens)

Anti-Infectives
Tazocin/Zosyn (tazobactam)
Tygacil (tigecycline)

Haemophilia
BeneFIX (recombinant Factor IX)
ReFacto (recombinant Factor VIII)

Immunology
Rapamune (sirolimus)

Oncology
Torisel (temsirolimus)

OPERATIONAL DATA
A wealth of background and detail
A full 5-year financial performance assessment
Key corporate events
Key agreements
Infrastructure
Subsidiaries and joint ventures


Summary: Pharmaceutical company intelligence reports provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.


Companies Mentioned Altana Pharma Amgen ArQule Inc Astellas Pharma Inc Cambridge Antibody Technology Ltd (CAT) Cardiokine Inc Celltech Chiroscience Corixa Corporation Curis Elan Corporation Exelixis Genzyme Biosurgery Inc Integra LifeSciences Corporation Intercell Karo Bio AB King Pharmaceuticals Inc Ligand Pharmaceuticals Inc Opsona Therapeutics Oxford BioMedica plc Pfizer Plexxikon Inc Progenics Pharmaceuticals Roche sanofi-aventis Schering-Plough Solvay Takeda Trubion Pharmaceuticals ViroPharma Zealand Pharmaceuticals A/S ZymoGenetics Inc


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/43088

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 02/12/2008 12:03:06
Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com


Order information

Please verify that the product information is correct and select the format you require.

Product Name:
Wyeth: Performance, Products, Pipeline and Potential
Web Address:
http://www.researchandmarkets.com/reports/43088
Office Code:
OCIFGONMSXS

Report formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €895.00
Hard Copy €895.00 + EUR€ 50.00 Shipping/Handling *

* Shipping/Handling is only charged once per order.


Contact information

Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World

Research and Markets Page 2 of 2
Printed 02/12/2008 12:03:06

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder Name:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.


If you have a Marketing Code please enter it below:

Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp



Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World